Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria

Background Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria. Method This was a retrospective, observational cohort study, using pharmacovigilance data systematically collected at all MDR-TB treatment centers in Nigeria. Characteristics of AEs during the intensive phase treatment were documented, and risk factors for development of AEs were assessed. Results Four hundred and sixty patients were included in the analysis: 62% were male; median age was 33 years [Interquartile Range (IQR):28–42] and median weight was 51 kg (IQR: 45–59). Two hundred and three (44%) patients experienced AEs; four died of conditions associated with SLD AEs. Gastro-intestinal (n = 100), neurological (n = 75), ototoxic (n = 72) and psychiatric (n = 60) AEs were the most commonly reported, whereas ototoxic and psychiatric AEs were the most debilitating. Majority of AEs developed after 1–2 months of therapy, and resolved in less than a month after treatment. Some treatment centers were twice as likely to report AEs compared with others, highlighting significant inconsistencies in reporting at different treatment centers. Patients with a higher body weight had an increased risk of experiencing AEs. No differences were observed in risk of AEs between HIV-infected and uninfected patients. Similarly, age was not significantly associated with AEs. Conclusion Patients in the Nigerian MDR-TB cohort experienced a wide range of AEs, some of which were disabling and fatal. Early identification and prompt management as well as standardized reporting of AEs at all levels of healthcare, including the community is urgently needed. Safer regimens for drug-resistant TB with the shortest duration are advocated.

[1]  D. Rosenbaum,et al.  Clinical research coordinator handbook : GCP tools and techniques , 2015 .

[2]  O. Oladimeji,et al.  Intensive-Phase Treatment Outcomes among Hospitalized Multidrug-Resistant Tuberculosis Patients: Results from a Nationwide Cohort in Nigeria , 2014, PloS one.

[3]  A. Mantel‐Teeuwisse,et al.  Adverse Events During Treatment of Drug-Resistant Tuberculosis: A Comparison Between Patients With or Without Human Immunodeficiency Virus Co-infection , 2013, Drug Safety.

[4]  P. V. van Helden,et al.  Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa , 2013, PloS one.

[5]  A. Sandgren,et al.  Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic Review , 2013, PloS one.

[6]  A. Diacon,et al.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.

[7]  G. Sotgiu,et al.  Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India , 2012, PloS one.

[8]  S. Pal,et al.  The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia , 2012, Southern med review.

[9]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[10]  C. Hallahan,et al.  Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  A. O. Afolabi,et al.  Knowledge, Attitude and Practice of Adverse Drug Reaction Reporting among Healthcare Workers in a Tertiary Centre in Northern Nigeria , 2011 .

[12]  O. Ogunleye,et al.  The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, south west Nigeria , 2011, Pharmacoepidemiology and drug safety.

[13]  O. Iribhogbe,et al.  Extent of pharmacovigilance among resident doctors in Edo and Lagos states of Nigeria , 2010, Pharmacoepidemiology and drug safety.

[14]  N. Awofeso Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. , 2008, Bulletin of the World Health Organization.

[15]  J. Andrews,et al.  Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. , 2007, The Journal of infectious diseases.

[16]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.

[17]  Douglas G Altman,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. , 2014, International journal of surgery.

[18]  A. Kehinde,et al.  Multidrug resistance to Mycobacterium tuberculosis in a tertiary hospital. , 2007, Journal of the National Medical Association.

[19]  I. Edwards,et al.  WHO Programme – Global Monitoring , 2007 .

[20]  B. Bıcakçı,et al.  Side effects associated with the treatment of multidrug-resistant tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  A. Rowhani-Rahbar,et al.  Barriers to completion of tuberculosis treatment among prisoners and former prisoners in St. Petersburg, Russia. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  T. Holtz,et al.  Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study , 2005, The Lancet.

[23]  P. Waller,et al.  Regulatory Pharmacovigilance in the EU , 2002 .

[24]  D. H. Mariam.,et al.  Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  D. Kennedy,et al.  Spontaneous Reporting in the United States , 2002 .

[26]  J. Rho,et al.  Counting the Costs of Drug-Related Adverse Events , 1999, PharmacoEconomics.

[27]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[28]  N. Moore,et al.  Frequency and cost of serious adverse drug reactions in a department of general medicine. , 1998, British journal of clinical pharmacology.

[29]  J. Griffin Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. , 1986, British journal of clinical pharmacology.

[30]  I. Oreagba,et al.  Impact of training on Nigerian healthcare professionals' knowledge and practice of pharmacovigilance. , 2013, The International journal of risk & safety in medicine.

[31]  J. Chinenye HEALTH WORKERS AND HOSPITAL PATIENTS KNOWLEDGE OF PHARMACOVIGILANCE IN SOKOTO, NORTH-WEST NIGERIA , 2012 .

[32]  E. Lopez-Gonzalez,et al.  Determinants of Under-Reporting of Adverse Drug Reactions , 2009, Drug safety.

[33]  L. Hazell,et al.  Under-Reporting of Adverse Drug Reactions , 2006, Drug safety.

[34]  J. Bartlett,et al.  Product information , 2001, Transplantation.

[35]  H T McGuigan,et al.  Health services. , 1975, The New Zealand medical journal.